Key Insights

Highlights

Treatment Research

2 treatments under study, led by 075 Ropivacaine 4mgml Dexamethasone Injection

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04085120Not ApplicableUnknownPrimary

Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain

Showing all 1 trials

Research Network

Common Treatments

  • 075 Ropivacaine 4mgml Dexamethasone Injection1
  • 10 Lignocaine Injection1

Active Sponsors

  • All India Institute of Medical Sciences1

Top Investigators

Related Conditions

  • Cancer Pain1
  • Pain Intractable1

Activity Timeline